Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical development company headquartered in Seattle, Washington. The company's mission is to transform cancer therapy by prioritizing patients and enhancing their quality of life, while relentlessly striving for a cure. It focuses on pioneering advanced treatments for various cancers throughout the body.

Perspective Therapeutics utilizes a proprietary technology that employs the alpha-emitting isotope Lead-212 (212Pb) to deliver potent radiation directly to cancer cells via specialized targeting peptides. This approach is integrated with complementary imaging diagnostics, often using Lead-203 (203Pb), to enable a "theranostic" platform for personalized treatment and optimized patient outcomes. The company's pipeline includes several clinical-stage programs in Phase 1/2a trials, such as VMT-α-NET for neuroendocrine tumors, VMT01 for metastatic melanoma, and PSV359 for FAP-α-expressing solid tumors. Additionally, Perspective Therapeutics markets CS-1 Cesium-131 brachytherapy seeds for various cancer indications.

Led by CEO Thijs Spoor, Perspective Therapeutics reported its full year 2025 results on March 16, 2026, disclosing a net loss of $103.1 million for the year, alongside a significant increase in research and development expenses. As of December 31, 2025, the company held approximately $145 million in cash and short-term investments, supplemented by $164 million in net proceeds from a February 2026 equity offering, which is projected to fund operations into late 2027. The company is actively expanding its regional network of drug product candidate finishing facilities to support its growing clinical and future commercial operations.